AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16641168 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-994 plus gemcitabine (CG)
Number of subjects: 174
Study 16641168 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (PG)
Number of subjects: 174
Study 14748311 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education alone
Number of subjects: 2203
Study 14748311 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education with shelf labeling
Number of subjects: 2203
Study 14748311 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2203
Study 11498678 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 9885072 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity strength training
Number of subjects: 36
Study 9885072 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity strength training
Number of subjects: 36
Study 9885072 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 8137469 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of TACE followed by PEI
Number of subjects: 24
Study 8137469 — intervention group
Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 24
Study 2913250 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.07 mg/kg
Number of subjects: 0
Study 2913250 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.10 mg/kg
Number of subjects: 0
Study 2913250 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.13 mg/kg
Number of subjects: 0
Study 1174050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl-3,5,6-tri-O-benzyl-D-glucofuranoside (tribenoside, Glyvenol)
Number of subjects: 5
Study 1174050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31756181 — intervention group
Group type: EXPERIMENTAL
Intervention: Zone distance varianceGLDZM
Number of subjects: 213
Study 31756181 — intervention group
Group type: EXPERIMENTAL
Intervention: Zone distance varianceGLDZM threshold of 1.70
Number of subjects: 213
Study 29117336 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin treatment
Number of subjects: 454
Study 29117336 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes using OV28 questionnaire
Number of subjects: 454
Study 29117336 — intervention group
Group type: COMPARATOR
Intervention: Clinician-reported neuropathy
Number of subjects: 454
Study 29117336 — intervention group
Group type: COMPARATOR
Intervention: Older age, bevacizumab treatment, bowel resection
Number of subjects: 454
Study 29117336 — intervention group
Group type: COMPARATOR
Intervention: Older age, volume of residual disease
Number of subjects: 454
Study 29117336 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPT additive polymorphisms
Number of subjects: 454
Study 29117336 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3B additive polymorphisms
Number of subjects: 454
Study 25414157 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks of antibiotic therapy
Number of subjects: 40
Study 25414157 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of antibiotic therapy
Number of subjects: 40
Study 24432669 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Qiangji Decoction (BQD) or Qingre Qiangji Decoction (QQD)
Number of subjects: 354
Study 24432669 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine enteric‐coated tablet (SECT)
Number of subjects: 354
Study 22900440 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol treatment (chewing gum for mothers and tablets for children, consumed three times/day for three months)
Number of subjects: 60
Study 22900440 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish (control group)
Number of subjects: 60
Study 22900440 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol treatment (experimental group)
Number of subjects: 60
Study 20183464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed effects model for repeated measurements (MMRM)
Number of subjects: 0
Study 20183464 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted generalized estimating equations (GEE)
Number of subjects: 0
Study 20183464 — intervention group
Group type: EXPERIMENTAL
Intervention: Unweighted generalized estimating equations (GEE)
Number of subjects: 0
Study 20183464 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-imputation-based GEE (MI-GEE)
Number of subjects: 0
Study 20183464 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete case (CC) analysis of covariance (ANCOVA)
Number of subjects: 0
Study 20183464 — intervention group
Group type: EXPERIMENTAL
Intervention: Last observation carried forward (LOCF) ANCOVA
Number of subjects: 0
Study 17166358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (infusion of insulin if blood glucose >6.1 mmol/L, maintenance at 4.4‐6.1 mmol/L)
Number of subjects: 116
Study 17166358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 116
Study 17166358 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (infusion of insulin if blood glucose >11.9 mmol/L, maintenance at 10.0‐11.1 mmol/L)
Number of subjects: 116
Study 15284112 — intervention group
Group type: EXPERIMENTAL
Intervention: R-FCM (rituximab + FCM)
Number of subjects: 147
Study 15284112 — intervention group
Group type: COMPARATOR
Intervention: FCM (fludarabine, cyclophosphamide, mitoxantrone)
Number of subjects: 147
Study 15284112 — intervention group
Group type: EXPERIMENTAL
Intervention: R-FCM
Number of subjects: 147
Study 11388528 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 60
Study 11388528 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60
Study 11388528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study 11388528 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide (N2O)
Number of subjects: 60
Study 9413892 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (Fenistil gel)
Number of subjects: 12
Study 9413892 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiderm
Number of subjects: 12
Study 9413892 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 12
Study 9413892 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylocain ointment 5%
Number of subjects: 12
Study 9413892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9413892 — intervention group
Group type: COMPARATOR
Intervention: Non-pretreated skin
Number of subjects: 12
Study 9413892 — intervention group
Group type: EXPERIMENTAL
Intervention: Alloknesis
Number of subjects: 12
Study 8214944 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) pretreatment (30 mg/kg)
Number of subjects: 0
Study 8214944 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid treatment (Control)
Number of subjects: 0
Study 3658289 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look laparotomy after comprehensive surgical staging and randomization into clinical protocols
Number of subjects: 112
Study 31115739 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold inspiratory muscle training (TIMT) for 12 weeks, 30–45 min/day, 5 days/week
Number of subjects: 16
Study 31880807 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 0
Study 31880807 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 28372309 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 30
Study 28372309 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 30
Study 25256795 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention (II) intervention with narrative healthy snacking scenarios
Number of subjects: 148
Study 25256795 — intervention group
Group type: COMPARATOR
Intervention: Implementation intention (II) intervention without narrative healthy snacking scenarios
Number of subjects: 148
Study 23356790 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50, and 70 mg/day
Number of subjects: 414
Study 23356790 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) (all doses)
Number of subjects: 414
Study 23356790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study 21666396 — intervention group
Group type: EXPERIMENTAL
Intervention: Glow gel hand washing without hand hygiene education
Number of subjects: 60
Study 21666396 — intervention group
Group type: EXPERIMENTAL
Intervention: Glow gel hand washing with hand hygiene education
Number of subjects: 60
Study 21666396 — intervention group
Group type: COMPARATOR
Intervention: Control group (parents)
Number of subjects: 60
Study 18443512 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for chronic postoperative groin pain
Number of subjects: 19
Study 18443512 — intervention group
Group type: COMPARATOR
Intervention: Preoperative pain
Number of subjects: 19
Study 18443512 — intervention group
Group type: COMPARATOR
Intervention: Postoperative pain
Number of subjects: 19
Study 17163237 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronic acid 70 mg weekly
Number of subjects: 936
Study 17163237 — intervention group
Group type: COMPARATOR
Intervention: Risedronic acid 35 mg weekly
Number of subjects: 936
Study 12544936 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplements
Number of subjects: 360
Study 10498386 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical care
Number of subjects: 2416
Study 8888353 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil with vitamin E (FO+E)
Number of subjects: 12
Study 8888353 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 12
Study 8888353 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study 2069096 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebufelone 50 mg
Number of subjects: 120
Study 2069096 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebufelone 100 mg
Number of subjects: 120
Study 2069096 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebufelone 200 mg
Number of subjects: 120
Study 2069096 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebufelone 25 mg
Number of subjects: 120
Study 2069096 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg ASA
Number of subjects: 120
Study 2069096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 7049154 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper 7 200 (Cu 7 200)
Number of subjects: 0
Study 7049154 — intervention group
Group type: COMPARATOR
Intervention: Multiload Copper 250 (ML Cu 250)
Number of subjects: 0
Study 31322739 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran 0.3 mg/kg intravenously every 3 weeks over 18 months
Number of subjects: 0
Study 31322739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31322739 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran 0.3 mg/kg
Number of subjects: 0
Study 30496705 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency cherry (MC) supplementation (235 mg/day anthocyanins)
Number of subjects: 12
Study 30496705 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 12
Study 30496705 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency cherry (MC) supplementation
Number of subjects: 12
Study 29391271 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA-FFA) 500 mg, twice daily for 6 months
Number of subjects: 60
Study 29391271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28760225 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 0
Study 28760225 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 24515505 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with parent-reported ASD
Number of subjects: 0
Study 24515505 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of children with ASD
Number of subjects: 0
Study 23028703 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio‐based Environment Simulator (AbES)
Number of subjects: 0
Study 23028703 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal directed gaming strategy
Number of subjects: 0
Study 23028703 — intervention group
Group type: EXPERIMENTAL
Intervention: AbES
Number of subjects: 0
Study 20026571 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and education schemes held twice weekly for eight weeks
Number of subjects: 243
Study 20026571 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 243
Study 16973901 — intervention group
Group type: EXPERIMENTAL
Intervention: Early movement of the ankle between neutral and plantar flexion in a brace for 6 weeks
Number of subjects: 50
Study 16973901 — intervention group
Group type: COMPARATOR
Intervention: Immobilization in tension using a below-knee cast with the ankle in a neutral position for 6 weeks
Number of subjects: 50
Study 16973901 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 11300442 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (bolus 0.25 mg/kg body weight, infusion 10 microg per min for 12 h)
Number of subjects: 60
Study 11300442 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (bolus 10 microg/kg, infusion 0.15 microg/kg per min for 72 h)
Number of subjects: 60
Study 11300442 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (bolus 180 microg/kg, infusion 2 microg/kg per min for 72 h)
Number of subjects: 60
Study 11300442 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 60
Study 11300442 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 60
Study 11300442 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 60
Study 9275887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographically guided technique
Number of subjects: 100
Study 9275887 — intervention group
Group type: COMPARATOR
Intervention: Anatomic landmark technique
Number of subjects: 100
Study 8093127 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium 99m nanocolloid
Number of subjects: 19
Study 8093127 — intervention group
Group type: COMPARATOR
Intervention: Indium 111 leucocytes
Number of subjects: 19
Study 3522528 — intervention group
Group type: EXPERIMENTAL
Intervention: Timentin (3 g/200 mg injections)
Number of subjects: 484
Study 3522528 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole (0.75 g injections)
Number of subjects: 484
Study 31609301 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Tyrosine (150 mg·kg)
Number of subjects: 9
Study 29498933 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol + folic acid (4000 mg myo-inositol + 400 μg folic acid per day)
Number of subjects: 3602
Study 29498933 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol + folic acid
Number of subjects: 3602
Study 29498933 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol
Number of subjects: 3602
Study 29498933 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3602
Study 26905565 — intervention group
Group type: EXPERIMENTAL
Intervention: MD-Knee (Group A)
Number of subjects: 60
Study 26905565 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate (Group B)
Number of subjects: 60
Study 25659187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone monotherapy for 12 weeks
Number of subjects: 120
Study 25659187 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks followed by ziprasidone for 6 weeks
Number of subjects: 120
Study 25659187 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 120
Study 23101474 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin and Sibling sample
Number of subjects: 377000
Study 23101474 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared environment factors
Number of subjects: 377000
Study 23101474 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral variation factors
Number of subjects: 377000
Study 20692693 — intervention group
Group type: EXPERIMENTAL
Intervention: PRB28 (peginterferon alfa‐2b, ribavirin, and boceprevir 800 mg three times a day for 28 weeks)
Number of subjects: 520
Study 20692693 — intervention group
Group type: EXPERIMENTAL
Intervention: PR4/PRB24 (peginterferon alfa‐2b and ribavirin for 4 weeks, followed by peginterferon alfa‐2b, ribavirin, and boceprevir for 24 weeks)
Number of subjects: 520
Study 20692693 — intervention group
Group type: EXPERIMENTAL
Intervention: PRB48 (peginterferon alfa‐2b, ribavirin, and boceprevir for 48 weeks)
Number of subjects: 520
Study 20692693 — intervention group
Group type: EXPERIMENTAL
Intervention: PR4/PRB44 (peginterferon alfa‐2b, ribavirin, and boceprevir for 44 weeks)
Number of subjects: 520
Study 20692693 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose PRB48 (low-dose ribavirin plus peginterferon alfa‐2b and boceprevir for 48 weeks)
Number of subjects: 520
Study 20692693 — intervention group
Group type: COMPARATOR
Intervention: PR48 (peginterferon alfa‐2b and ribavirin for 48 weeks)
Number of subjects: 520
Study 18379219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophy protocol (4 sets, 10 repetitions, 90 s rest at 75% 1RM)
Number of subjects: 10
Study 18379219 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength protocol (11 sets, 3 repetitions, 5 min rest at 90% 1RM)
Number of subjects: 10
Study 16777271 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune modulating jejunostomy feeding (Stresson-Group A)
Number of subjects: 120
Study 16777271 — intervention group
Group type: COMPARATOR
Intervention: Standard isonitrogenous, isocaloric feed (Nutrison High Protein-Group B)
Number of subjects: 120
Study 12666038 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal factors including miscarriage symptoms, premature delivery symptoms, severe flu attacks, tobacco abuse, alcohol abuse, minor congenital malformations, neonatal seizures, and hospitalizations during newborn period.
Number of subjects: 200
Study 12666038 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature delivery symptoms, severe flu attacks, and neonatal seizures (identified through stepwise logistic multiple regression analysis).
Number of subjects: 200
Study 11009262 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting in ESRD patients
Number of subjects: 34
Study 11009262 — intervention group
Group type: COMPARATOR
Intervention: Coronary stenting in control group (non-ESRD)
Number of subjects: 34
Study 11009262 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality in ESRD patients
Number of subjects: 34
Study 11009262 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality in control group (non-ESRD)
Number of subjects: 34
Study 8774326 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive, supervised aerobic walking programme for 52 weeks
Number of subjects: 21
Study 8774326 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 21
Study 1612374 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation/Endoscopy
Number of subjects: 66
Study 1612374 — intervention group
Group type: COMPARATOR
Intervention: Radiography
Number of subjects: 66
Study 30074007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Molar
Number of subjects: 30
Study 30074007 — intervention group
Group type: EXPERIMENTAL
Intervention: Photac Fil
Number of subjects: 30
Study 30074007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract XP
Number of subjects: 30
Study 26854486 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (0.25 mg/kg/day)
Number of subjects: 156
Study 26854486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 26854486 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 156
Study 26854486 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin and Placebo
Number of subjects: 156
Study 24156269 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine treatment
Number of subjects: 303
Study 22906061 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain coping skills training
Number of subjects: 402
Study 22906061 — intervention group
Group type: COMPARATOR
Intervention: Arthritis education control
Number of subjects: 402
Study 22906061 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 402
Study 20524999 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (0.066 mg/kg, max 4 mg)
Number of subjects: 13
Study 20524999 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 13
Study 20524999 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 13
Study 20524999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 20524999 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid and Placebo
Number of subjects: 13
Study 17768587 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (three fast 30-minute walks and two sessions of one-hour training per week)
Number of subjects: 112
Study 17768587 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 112
Study 17768587 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 112
Study 17768587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity intention to treat analysis
Number of subjects: 112
Study 16624969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen use 1 or 2 days per week
Number of subjects: 139
Study 16624969 — intervention group
Group type: COMPARATOR
Intervention: Sunscreen use daily
Number of subjects: 139
Study 16624969 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent outdoors
Number of subjects: 139
Study 16624969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen use
Number of subjects: 139
Study 12654707 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (800 microg/min)
Number of subjects: 20
Study 12654707 — intervention group
Group type: COMPARATOR
Intervention: Candesartan (800 microg/min) + Icatibant (90 microg/min)
Number of subjects: 20
Study 12654707 — intervention group
Group type: COMPARATOR
Intervention: Candesartan (800 microg/min) + L-NMMA (7 micromol/min)
Number of subjects: 20